HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma

Gynecologic Oncology

Volumn 96, Issue 1, 2005, Pages 42-47

  Davidson, Ben ^a   Elstrand, Mari Bukholt ^a   McMaster, Michael T ^b   Berner, Aasmund ^a   Kurman, Robert J ^c   Risberg, Björn ^a   Trope, Claes G ^a   Shih, Ie Ming ^c  

^a UNIVERSITY OF OSLO   (Norway)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Chemotherapy; Effusions; Immune response; Ovarian carcinoma; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; HLA G ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HLA SYSTEM; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; STATISTICAL ANALYSIS; TUMOR CELL;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ASCITIC FLUID; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLEURAL EFFUSION; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 10044255346     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.09.049     Document Type: Article

References (21)

1. H. Jemal, T. Murray, A. Samuels, A. Ghafoor, E. Ward, and M. Thun Cancer statistics, 2003 CA Cancer J. Clin. 53 2003 5 26
2. B. Davidson, R. Risberg, R. Reich, and A. Berner Effusion cytology in ovarian cancer-new molecular methods as aids to diagnosis and prognosis Clin. Lab. Med. 23 2003 729 754
3. B. Davidson Malignant effusions-from diagnosis to biology Diagn. Cytopathol. 31 2004 Z46 Z54
4. K. van der Ven, K. Pfeiffer, and S. Skrablin HLA-G polymorphisms and molecule function-questions and more questions-a review Placenta 21 Suppl. A 2000 S86 S92
5. M. McMaster, Y. Zhou, S. Shorter, K. Kapasi, D. Geraghty, and K.H. Lim HLA-G isoforms produced by placental cytotrophoblasts and found in amniotic fluid are due to unusual glycosylation J. Immunol. 160 1998 5922 5928
6. M.T. McMaster, C.L. Librach, Y. Zhou, K.H. Lim, M.J. Janatpour, and R. DeMars Human placental HLA-G expression is restricted to differentiated cytotrophoblasts J. Immunol. 154 1995 3771 3778
7. G. Singer, R.J. Kurman, M. McMaster, and I.-M. Shih HLA-G immunoreactivity is specific for intermediate trophoblast in gestational trophoblastic disease and can serve as a useful marker in differential diagnosis Am. J. Surg. Pathol. 26 2002 914 920
8. L.M. Real, T. Cabrera, A. Collado, P. Jimenez, A. Garcia, and F. Ruiz-Cabello Expression of HLA-G in human tumors is not a frequent event Int. J. Cancer 81 1999 512 518
9. P. Paul, N. Rouas-Freiss, I. Khalil-Daher, P. Moreau, B. Riteau, and F.A. Le Gal HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance Proc. Natl. Acad. Sci. U. S. A. 95 1998 4510 4515
10. E.C. Ibrahim, N. Guerra, M.J. Lacombe, E. Angevin, S. Chouaib, and E.D. Carosella Tumor-specific up-regulation of the nonclassical class I HLA-G antigen expression in renal carcinoma Cancer Res. 61 2001 6838 6845
11. M. Urosevic, M.O. Kurrer, J. Kamarashev, B. Mueller, W. Weder, and G. Burg Human leukocyte antigen G up-regulation in lung cancer associates with high-grade histology, human leukocyte antigen class I loss and interleukin-10 production Am. J. Pathol. 159 2001 817 824
12. S. Lefebvre, M. Antoine, S. Uzan, M. McMaster, J. Dausset, and E.D. Carosella Specific activation of the non-classical class I histocompatibility HLA-G antigen and expression of the ILT2 inhibitory receptor in human breast cancer J. Pathol. 196 2002 266 274
13. M. Urosevic, J. Willers, B. Mueller, W. Kempf, G. Burg, and R. Dummer HLA-G protein up-regulation in primary cutaneous lymphomas is associated with interleukin-10 expression in large cell T-cell lymphomas and indolent B-cell lymphomas Blood 99 2002 609 617
14. G. Singer, V. Rebmann, Y.C. Chen, H.T. Liu, S.Z. Ali, and J. Reinsberg HLA-G is a potential tumor marker in malignant ascites Clin. Cancer Res. 9 2003 4460 4464
15. B. Davidson, B. Risberg, G. Kristensen, G. Kvalheim, E. Emilsen, and A. Bjåmer Detection of cancer cells in effusions from patients diagnosed with gynecological malignancies-evaluation of five epithelial markers Virchows Arch. 435 1999 43 49
16. B. Davidson, A. Berner, J.M. Nesland, B. Risberg, G.B. Kristensen, and C.G. Trope Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma-evidence of up-regulated Tn and Sialyl Tn antigens expression in effusions Hum. Pathol. 31 2000 1081 1087
17. B. Davidson, S. Nielsen, J. Christensen, P. Asschenfeldt, A. Berner, and B. Risberg The role of Desmin and N-cadherin in effusion cytology. A comparative study using established markers of mesothelial and epithelial cells Am. J. Surg. Pathol. 25 2001 1405 1412
18. R.H. Young, P.B. Clement, and R.E. Scully Surface epithelial-stromal tumors S.S. Sternberg D.A. Antonioli D. Carter S.E. Mills H.A. Oberman Diagnostic surgical pathology 1999 Lippincott Williams and Wilkins Philadelphia 2319 2382
19. M.A. Nash, R. Lenzi, C.L. Edwards, J.J. Kavanagh, A.P. Kudelka, and C.F. Verschraegen Differential expression of cytokine transcripts in human epithelial ovarian carcinoma by solid tumour specimens, peritoneal exudate cells containing tumour, tumor-infiltrating lymphocyte (TIL)-derived T cell lines and established tumour cell lines Clin. Exp. Immunol. 112 1998 172 180
20. D. Milliken, C. Scotton, S. Raju, F. Balkwill, and J. Wilson Analysis of chemokines and chemokine receptor expression in ovarian cancer ascites Clin. Cancer Res. 8 2002 1108 1114
21. V. Givant-Horwitz, B. Davidson, P. Lazarovici, E. Schaefer, J.M. Nesland, and C.G. Trope Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions Gynecol. Oncol. 91 2003 160 172